Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics’ SEC disclosures don’t just list numbers—they unpack gene-therapy science, TRACER™ capsid breakthroughs, and clinical trial risks that shape the company’s future. Yet finding R&D burn rates, partnership milestone payments, or CNS efficacy data inside a 200-page 10-K can feel daunting.
Stock Titan solves that problem. Our AI reads every Voyager Therapeutics annual report 10-K simplified, each Voyager Therapeutics quarterly earnings report 10-Q filing, and even those time-sensitive 8-K material events explained, surfacing what matters most: trial updates, cash runway changes, and FDA feedback. Interactive summaries translate dense biotech language into plain English so you spend minutes—not hours—understanding Voyager Therapeutics SEC filings explained simply.
Need to monitor management moves? Receive Voyager Therapeutics Form 4 insider transactions real-time, including executive stock transactions Form 4, so you can spot buying or selling before crucial data releases. Follow compensation shifts through the Voyager Therapeutics proxy statement executive compensation section, and track funding trends with our Voyager Therapeutics earnings report filing analysis.
Because filings post without warning, we deliver real-time alerts the moment EDGAR releases a document. Investors use these insights to:
- Compare quarter-over-quarter R&D spend against cash reserves
- Verify milestone revenue from licensing deals
- Gauge regulatory momentum via 8-K event updates
- Cross-reference Voyager Therapeutics insider trading Form 4 transactions with trial timelines
Whether you’re understanding Voyager Therapeutics SEC documents with AI or tracking Voyager Therapeutics 8-K material events explained, our platform brings every disclosure into focus so you can make informed decisions on this pioneering CNS gene-therapy company.
Voyager Therapeutics, Inc. filed a mixed shelf registration to offer up to $400,000,000 of securities, including common and preferred stock, debt, depositary shares, subscription rights, warrants, purchase contracts, and units, in one or more offerings after this registration statement becomes effective.
The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock with TD Securities (USA) LLC (TD Cowen), which is part of the $400,000,000 shelf. Proceeds, if and when raised, may be used for general corporate purposes such as R&D, advancing programs into clinical development, regulatory activities, working capital, and potential in-licenses or acquisitions. Voyager’s common stock trades on Nasdaq as VYGR. Shares outstanding were 55,600,084 as of November 3, 2025.
Voyager Therapeutics reported Q3 2025 results showing lower collaboration revenue and a wider loss as it advances its neurology pipeline. Collaboration revenue was $13.4 million versus $24.6 million a year ago, while operating expenses rose to $44.0 million from $38.4 million, driving a net loss of $27.9 million compared with $9.0 million in Q3 2024. For the first nine months, collaboration revenue was $25.0 million versus $73.7 million a year earlier, with a net loss of $92.3 million.
Cash, cash equivalents, and marketable securities totaled $229.0 million as of September 30, 2025, and management expects this to fund operations for at least 12 months. The company continues to invest in Alzheimer’s programs VY7523 (anti‑tau antibody, Phase 1 MAD started in early AD) and VY1706 (tau‑silencing gene therapy, IND planned in 2026). A subsequent event notes Novartis’ partial termination of a 2022 option and license agreement for two programs effective February 1, 2026; one Novartis program remains under that agreement.
Voyager Therapeutics, Inc. (VYGR) Chief Financial Officer Nathan D. Jorgensen reported the sale of 7,666 shares of common stock on
Voyager Therapeutics (VYGR) filed a Form 144 notice for a proposed sale of 5,843 common shares. The shares carry an aggregate market value of $27,936.55 and are slated for sale through Fidelity Brokerage Services LLC on or about 10/03/2025 on the NASDAQ.
The securities were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. This is a routine compliance notice that permits the holder to sell these shares under Rule 144, subject to applicable volume and manner-of-sale conditions.
VYGR: A holder filed a Form 144 notice to sell 7,666 shares of common stock. The filing lists an aggregate market value of $36,633.51 and an approximate sale date of 10/03/2025, with sales through Fidelity Brokerage Services LLC on NASDAQ.
The shares were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 55,468,806; this is a baseline figure, not the amount being sold.
Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported the sale of 19,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $3.73 per share. After the reported sale, Mr. Ferguson beneficially owned 138,914 shares, held directly. The filing discloses that the $3.73 figure is a weighted average for multiple transactions executed at prices ranging from $3.69 to $3.79 and states the reporting person will provide a detailed breakdown of shares sold at each price on request. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Voyager Therapeutics, Inc. (VYGR) filed a Form 144 notifying a proposed sale of 19,000 common shares that vested as restricted stock on 04/01/2025. The shares are held at Fidelity Brokerage Services and were acquired as compensation. The filer estimates an aggregate market value of $70,680 and reports 55,468,806 shares outstanding; the approximate sale date is 08/18/2025 on NASDAQ. The filer reports no sales in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 4,800,000 shares of Voyager Therapeutics, Inc. common stock, representing 8.65% of the outstanding shares based on 55,468,806 shares outstanding. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and that Armistice exercises shared voting and dispositive power over the reported shares. Neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the holder with the right to receive proceeds or dividends.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
